Российский кардиологический журнал

Расширенный поиск


Полный текст:

Список литературы

1. WHO-FIC Network at the annual meeting in Trieste, October 2007. classifications/icd/ICD-10%20Updates%202007.pdf

2. Matsushita K, van der Velde M, Astor BC, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all- cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375 (9731):2073-81.

3. Ronco C, McCullough P, Anker S, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010;31:703-11.

4. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359: 2417-28.

5. Bakris GL, Sera dis PA, Weir MR, et al. ACCOMPLISH Trial Investigators. Renal outcomes with different xed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of randomized controlled trial. Lancet 2010;375: 1173-81.

6. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.

7. de Galan BE, Perkovic V, Ninomiya T, et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92.

8. Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.

9. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367 (24):2296-304.

10. Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial. Lancet 2008;372:547-53.

11. Haller H, Ito S, Izzo JL Jr, et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17.

12. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377 (9784):2181-92.

13. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Смирнов А.В., Шилов Е.М., Добронравов В.А., Каюков И.Г., Бобкова И.Н., Швецов М.Ю., Цыгин А.Н., Шутов А.М. Нефрология. 2012. Т. 16. №1. С.89-115.

14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int (Suppl.) 2013;3:1-150.

15. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60 (5):850-886.

16. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int, (Suppl) 2012;2:1-138.

17. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.

18. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика, 2011; 10 (6). Приложение 2. http://

19. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.

20. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Москва, 2012 г.

21. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.

22. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int. (Suppl.) 2013;3:259-305.

23. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации ВНОК и НОНР. Кардиоваскулярная терапия и профилактика. 2008;7 (6), Приложение 3.

24. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter., Suppl. 2012;2:

25. Клинические практические рекомендации KDIGO по анемии при хронической болез¬ни почек 2012. Нефрология и диализ 2013;15 (1):14-53.

26. Национальные рекомендации по минеральным и костным нарушениям при хро¬нической болезни почек. Российское диализное общество. Нефрология и диализ. 2011;13 (1):33-51.

27. Hemmelgarn BR, Manns BJ, Tonelli M; Interdisciplinary Chronic Disease Collaboration/ A decade after the KDOQI CKD Guidelines: a perspective from Canada. Am J Kidney Dis. 2012;60 (5):723-4.

28. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.

29. Middleton RJ, Foley RN, Hegarty J, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006;21:88-92.

30. Segura J, Garcia-Donair J, Praga M, et al. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol 2006;17 (Suppl 2.):136-40.

31. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45 (Suppl 3): S1-153.

32. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.

33. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41 (1):47-55.

34. Foley R, Murray A, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95.

35. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002;13 (5):1338-49.

36. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.

37. Collins AJ, Vassalotti JA, Wang C, et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease. Am J Kidney Dis 2009;53 (Suppl 3): 71-7.

38. Herzog C. Kidney disease in cardiology. Nephrol Dial Transplant 2008;23 (8):42-46.

39. McCullough PA, Li S, Jurkovitz CT, et al. CKD and cardiovascular disease in screened high- risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008;51 (Suppl 2):38-45.

40. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28,1462-1536.

41. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142:342-51.

42. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292: 2343-2349.

43. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6.

44. Okin PM, Oikarinen L, Viitasalo M, et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation 2009;119:1883-91.

45. Olsen MH, Wachtell K, Ibsen H, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006;24:775-81.

46. Schmieder RE, Mann JF, Schumacher H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011;22:1353-64.

47. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010;56:956-65.

48. Wilson P, D'Agostino Rb, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72.

49. Кобалава Ж. Д., Моисеев В. С. Концепция кардиоренальных и метаболических соот¬ношений в современной профилактической кардиологии. Кардиоваскулярная тера¬пия и профилактика. 2008;4:4-7.

50. Despres J.— P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J 2006;8 (suppl. B):4-12.

51. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003;26:360-6.

52. Алгоритмы специализированной медицинской помощи больным сахарным диа¬бетом. Под ред. Дедова И. И., Шестаковой М. В. 6-й вып. М., 2013. http://www.

53. Мухин Н. А., Балкаров И. М., Моисеев В. С. и др. Хронические прогрессирую¬щие нефропатии и образ жизни современного человека. Терапевтический архив 2004;9:5-10.

54. Кобалава Ж.Д., Котовская Ю. В., Толкачева В. В., Мильто А. С. Мочевая кислота — ключевой компонент кардиренометаболического континуума. Кардиоваскулярная терапия и профилактика. 2008;4:95-100.

55. Ronco C, McCullough P, Anker S, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010;31:703-11.

56. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J 2005;149:209-16.

57. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 2007;50:768-77.

58. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.

59. Munar MY Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Phys 2007;75 (10):1487-96.

60. Roghi A, Savonitto S, Cavallini C, et al. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med 2008;9:375-81.

61. Lassnigg A, Schmid ER, Hiesmayr M, et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med 2008;36:1129-37.

62. Bagshaw SM, Lapinsky S, Dial S, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009;35:871-81.

63. Latchamsetty R, Fang J, Kline-Rogers E, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol 2007;99 (7):939-42.

64. Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006;17:2886-91.

65. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-41.

66. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients >65 years of age with heart failure. Am J Card. 2000;85:1110-3.

67. Cowie MR, Komajda M, Murray-Thomas T, et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006;27:1216-22.

68. Ronco C, Bellomo R, McCullough PA. Cardiorenal syndromes in critical care. Contrib Nephrol. 2010; Basel, Karger, 2010, vol 165, 366 p.

69. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. Am Heart J 2008;155:725-31.

70. Gibson CM, Dumaine RL, Gelfand EV, et al: Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: Observations in 13,307 patients in five TIMI trials. Eur Heart J 2004;25 (22):1998-2005.

71. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-619.

72. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 2010;268:40-9.

73. Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007;147:304-10.

74. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-67.

75. Alexander KP, Chen AY Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-16.


Для цитирования:

Моисеев В.С., Мухин Н.А., Смирнов А.В., Кобалава Ж.Д., Бобкова И.Н., Виллевальде С.В., Ефремовцева М.А., Козловская Л.В., Швецов М.Ю., Шестакова М.В., Арутюнов Г.П., Бойцов С.А., Галявич А.С., Гринштейн Ю.И., Добронравов В.А., Драпкина О.М., Ермоленко В.М., Карпов Ю.А., Каюков И.Г., Котовская Ю.В., Кухарчук В.В., Мартынов А.И., Морозова Т.Е., Оганов Р.Г., Подзолков В.И., Рожинская Л.Я., Терещенко С.Н., Фомин В.В., Хирманов В.Н., Чазова И.Е., Шамхалова М.Ш., Шилов Е.М., Шляхто Е.В., Шутов А.М. СЕРДЕЧНО-СОСУДИСТЫЙ РИСК И ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК: СТРАТЕГИИ КАРДИО-НЕФРОПРОТЕКЦИИ. Российский кардиологический журнал. 2014;(8):7-37.

For citation:

Moiseev V.C., Mukhin N.A., Smirnov A.V., Kobalava J.D., Bobkova I.N., Villevalde S.V., Yefremovtseva M.A., Kozlovskaya L.V., Shvetsov M.Yu., Shestakova M.V., Arutyunov G.P., Boytsov S.A., Galyavich A.S., Greenstein Y.I., Dobronravov V.A., Drapkina O.M., Ermolenko V.M., Karpov Yu.A., Kayukov I.G., Kotovsky J.V., Kukharchuk V.V., Martynov A.I., Morozova T.E., Oganov R.G., Podzolkov V.I., Rozhinskaya L.Y., Tereshchenko S.N., Fomin V.V., Khirmanov V.N., Chazova I.E., Shamkhalova M.S., Shilov E.M., Shlyakhto E.V., Shutov A.M. CARDIOVASCULAR RISK AND CHRONIC KIDNEY DISEASE: CARDIO-NEPHROPROTECTION STRATEGIES. Russian Journal of Cardiology. 2014;(8):7-37. (In Russ.)

Просмотров: 1589

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)